News Channels

12 Jun 2017 Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
12 Jun 2017 Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
12 Jun 2017 Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Finland, company expands on development plan
12 Jun 2017 Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer
12 Jun 2017 vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions
12 Jun 2017 Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
12 Jun 2017 Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 topre-clinical development
11 Jun 2017 Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome
11 Jun 2017 Catalyst Biosciences Announces Presentations on its Next-Generation Subcutaneous Hemophilia Product Candidates at the 2017 International Society on Thrombosis and Haemostasis (ISTH) Meeting
11 Jun 2017 AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study
11 Jun 2017 Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions
11 Jun 2017 Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions
11 Jun 2017 Merz Neurosciences Announces Positive Phase III Results of Xeomin® (IncobotulinumtoxinA) for Sialorrhea at 2017 MDS Meeting
11 Jun 2017 Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients
11 Jun 2017 Tyrogenex Announces Publication of Phase 1 Data for X-82 for the Oral Treatment of Neovascular Age-Related Macular Degeneration in the Journal of the American Medical Association
11 Jun 2017 Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
11 Jun 2017 Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies
11 Jun 2017 Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
11 Jun 2017 FDA requests removal of Opana ER for risks related to abuse
11 Jun 2017 Lilly Announces Strategic Collaboration with KeyBioscience AG

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top